Radiopharmaceutical Theranostics Market: How Is Lutetium-177 PSMA...

adicionou um novo artigo Health

2026-04-14 11:13:34 -

Radiopharmaceutical Theranostics Market: How Is Lutetium-177 PSMA Therapy Transforming Prostate Cancer?

Lutetium-177 PSMA radioligand therapy — the targeted radionuclide treatment delivering beta-emitting Lu-177 directly to prostate-specific membrane antigen-expressing prostate cancer cells — represents the most commercially significant radiopharmaceutical theranostics launch in the market's history, with the Radiopharmaceutical Theranostics Market reflecting Lu-177 PSMA as the...

0 Comentários 0 Compartilhamentos 9 Visualizações 0 Anterior